Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2025-08-14 00:00:00 ET · period of report 2025-08-12 · accession 0001104659-25-078814 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-08-14 | 2025-08-12 | RYTM | German Christopher Paul | CAO, Corp. Ctrl | M - OptEx | $28.39 | +1,500 | 1,422 | New | +$42.6K |
| D | 2025-08-14 | 2025-08-12 | RYTM | German Christopher Paul | CAO, Corp. Ctrl | S - Sale+OE | $95.00 | -1,500 | 922 | -62% | -$142.5K |
| DM | 2025-08-14 | 2025-08-12 | RYTM | German Christopher Paul | CAO, Corp. Ctrl | M - OptEx | $0.00 | -1,500 | 5,231 | -22% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-12 | M | A | 1,000 | $17.97 | 1,922 | D | — | — | |
| 2 | Common | Common Stock | 2025-08-12 | M | A | 500 | $49.23 | 1,422 | D | — | — | |
| 3 | Common | Common Stock | 2025-08-12 | S | D | 1,500 | $95.00 | 922 | D | — | — | |
| 4 | Derivative | Stock Options (Right to Buy) | 2025-08-12 | M | D | 500 | $0.00 | 4,050 | D | $49.23 · — to 2034-02-15 | 500 Common Stock | (F3) The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
| 5 | Derivative | Stock Options (Right to Buy) | 2025-08-12 | M | D | 1,000 | $0.00 | 5,231 | D | $17.97 · — to 2033-04-03 | 1,000 Common Stock | (F2) The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. |